Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies-Reference-Cited by-同舟云学术

Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies

Published:2018-06-12 Issue:1 Volume:60 Page:238-241
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Bertoli Sarah¹²³,Tavitian Suzanne¹,Berard Emilie⁴⁵,Gadaud Noemie¹,Luquet Isabelle⁶,Huynh Anne¹,Sarry Audrey¹,Huguet Françoise¹,Récher Christian¹²³

Affiliation:

1. Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France;

2. Faculté de médecine, Université Toulouse III Paul Sabatier, Toulouse, France;

3. Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France;

4. Service d'Epidemiologie, CHU de Toulouse, Toulouse, France;

5. UMR1027, INSERM-Université Toulouse III, Toulouse, France;

6. Laboratoire d’Hematologie, CHU de Toulouse, Toulouse, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1464156

Reference12 articles.

1. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

2. How I treat refractory and early relapsed acute myeloid leukemia

3. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

4. Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

5. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients;Acute Myeloid Leukemia;2021

2. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2020-11

3. Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors;Leukemia & Lymphoma;2019-09-30